Our data show for the first time that increasing miR-342-5p intrinsically reduces imatinib resistance in CMLMiR-342-5p acts as a tumor suppressor in CML by suppressing the expression of BCR-ABL and CCND1 (Figs. 2 and 3). This evidence concerns the gene CCND1 and neoplasm.